Synthetic Molecule Effectively Targets Breast and Pancreatic Cancers in Just Three Doses
Scientists at Stanford have developed a synthetic molecule, PIP-CpG, that targets and kills breast and pancreatic cancers in mice with as few as three doses by delivering immune-activating agents directly to tumors, transforming the tumor microenvironment and showing promising results for future human treatments.